Skip to content
Palanor is in early release, with our founding customers.Become a founding customer →
The Real Rate Index45.30.00Palanor: Inflation Pulse50.7+0.09Palanor: Geopolitical Stress60.0-2.16Palanor: Liquidity57.9-0.79Palanor: Capital Tightness47.5+0.91Palanor: Industrial Pulse70.10.00Palanor: AI Margin Compression53.4+0.29Palanor: Consumer Confidence48.6+0.50Palanor: US Dollar Strength46.50.00Palanor: Labor Heat63.2-0.01Palanor: Recession Vocabulary28.1+0.54Palanor: Uncertainty Index53.4+1.24Palanor: US Jobs Health40.30.00Palanor: Energy Transition37.0-0.52Palanor: Reshoring Sentiment22.8+0.54Palanor: AI Substitution28.4-0.24The Social Fabric Index45.70.00Palanor: Geopolitical Anxiety19.4-0.45Palanor: Quit Pressure37.6+0.42The Mania Index88.00.00The Palanor Index57.1-0.51Cost Disease Spread33.20.00Palanor: US vs China49.5-0.17Rise of Socialism Index40.8-0.26The Bubble Memory79.90.00Palanor: Steward Confidence50.8+0.13The Long Watch90.30.00The Reshoring Index55.2+0.00The Capital Return Index81.0-0.75The Discourse Index72.4+1.83The Hesitation Index30.8-6.58Palanor AI Inference Cost Index71.2-0.03The AI Capex Race Index78.4+1.36The Boardroom Index82.5-0.00The Layoff Cycle Index32.8-2.51Capital Deployment Posture Index62.3+1.26The Consumer Health Index41.7-2.96Labor Hours Composite44.40.00The Dollar Erosion Index66.6+0.14Palanor: Risk Appetite36.2+0.83
PalanorPalanor

Company Dossier · Health Care

Arrowhead Pharmaceuticals

ARWRNasdaqBiotechnologyCAMDEN, US-DE, USMid capWebsite ↗
  • Russell 1000
  • MidCap 400

What Arrowhead Pharmaceuticals is doing, read from its filings, its own words and the news, with every figure dated and sourced. Not investment advice: no ratings, no price targets.

Open the full company record in Palanor: guidance, KPIs, ownership, calls, prices →

The latest read

Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.

  • Revenue over the four quarters to June 30, 2026: $0.67 billion, up 18% from a year earlier.SEC EDGAR filings (XBRL)
  • Free cash flow (operating cash flow minus capital expenditure) over the four quarters to June 30, 2026: −$0.08 billion.SEC EDGAR filings (XBRL)
  • Capital expenditure over the four quarters to June 30, 2026: $0.02 billion, down 50% from a year earlier.SEC EDGAR filings (XBRL)
  • Latest earnings call or results release (August 4, 2026): sentiment 0.80 on a −1 to +1 scale (confident, opportunity-framed), confidence 0.90 of 1.Palanor Discourse
  • Latest annual report (filed November 25, 2025): 3 risk factors added, 0 removed.Risk Factor Changes (10-K Item 1A)
  • Insiders were net sellers in Q3 2026: $1.2 million on the open market.SEC Form 4
  • 499 institutional managers reported a position at June 30, 2026 (+62 on the quarter before).SEC Form 13F
  • H-1B filings certified in Q2 2026: 2 (1 a year earlier).U.S. Department of Labor (OFLC)

Company Posture

How Company Posture is measured →

Company Posture covers S&P 500 companies.

Credit

How these are built →

No bond term sheets or tagged debt on file for Arrowhead Pharmaceuticals yet.

Charts

Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.

Cash flow

Business

Arrowhead Pharmaceuticals: free cash flow, trailing twelve months

Operating cash flow minus capital expenditure, $ billions, from SEC filings

−$0.08BData to Jun 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Arrowhead Pharmaceuticals: operating cash flow and capital expenditure

Trailing twelve months, $ billions, from SEC filings

Data to Jun 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Arrowhead Pharmaceuticals: revenue, trailing twelve months

$ billions, from SEC filings

$0.7BData to Jun 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR

Capital returned and raised

Business

Arrowhead Pharmaceuticals: debt due within a year and cash

At each balance-sheet date, $ billions, from SEC filings

Data to Jun 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Arrowhead Pharmaceuticals: interest coverage

Operating income ÷ interest expense, trailing twelve months, from SEC filings

−2Data to Jun 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR

What the company says

Business

Arrowhead Pharmaceuticals: earnings call sentiment

Palanor Discourse score per call, −1 to +1

0.80Data to Aug 2026
ImageDataPalanor calculation
Business

Arrowhead Pharmaceuticals: earnings call confidence

Palanor Discourse score per call, 0 to 1

0.90Data to Aug 2026
ImageDataPalanor calculation
Business

Arrowhead Pharmaceuticals: risk factors added per annual report

New Item 1A risk factors in each 10-K

3.0Data to Nov 2025
ImageDataU.S. Securities and Exchange Commission, EDGAR

Hiring and ownership

Business

Arrowhead Pharmaceuticals: H-1B filings certified

Labor Condition Applications by quarter received

2.0Data to Jun 2026
ImageDataU.S. Department of Labor, Office of Foreign Labor Certification disclosure data, dol.gov
Business

Arrowhead Pharmaceuticals: insider net buying

Open-market purchases minus sales by officers and directors, $ millions, by quarter

−$1.2MData 22 days ago
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Arrowhead Pharmaceuticals: institutional holders

Managers reporting a position on Form 13F, by quarter

499.0Data to Jun 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR

In the news

Headlines that name Arrowhead Pharmaceuticals, with the publisher and a link. The tone is read from each headline’s own words, never from a summary of the article.

30 days
2 headlines
0% positive · 0% negative
90 days
2 headlines
0% positive · 0% negative

Filings and records

The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.

  1. Sep 23, 2026Trademark
    Trademark application: LOWISGO
  2. Sep 23, 2026Trademark
    Trademark application: ZODEZLO
  3. Sep 23, 2026Trademark
    Trademark application: ZOVEMLO
  4. Sep 8, 2026Patent
    Patent granted: RNAi Agents And Compositions for Inhibiting Expression of Angiopoietin-Like 3 (ANGPTL3), And Methods Of UseUS 12729377
  5. Jun 30, 2026Patent
    Patent granted: INTEGRIN TARGETING LIGANDS AND USES THEREOFUS 12667619
  6. Jun 16, 20268-K
    Director or officer changeItem 5.02
  7. Jun 16, 2026Patent
    Patent granted: RNAi Agents for Inhibiting Expression of Beta-ENaC, Compositions Thereof, and Methods of UseUS 12655428
  8. May 19, 2026Patent
    Patent granted: RNAi Agents for Inhibiting Expression of Xanthine Dehydrogenase (XDH), Pharmaceutical Compositions Thereof, and Methods of UseUS 12630826
  9. Mar 24, 2026Patent
    Patent granted: METHODS FOR THE TREATMENT OF ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD)US 12582668
  10. Mar 20, 20268-K
    Shareholder vote resultsItem 5.07
  11. Jan 12, 20268-K
    Material agreement signedItem 1.01
  12. Jan 9, 20268-K
    Material agreement signedItem 1.01
  13. Nov 25, 202510-K
    Annual report (10-K)3 risk factors added, 0 removed
  14. Oct 21, 2025Trademark
    Trademark application: RELY ON REDEMPLO
  15. Sep 2, 20258-K
    Material agreement signedItem 1.01
  16. Jul 30, 2025Trademark
    Trademark application: REDEMPLO
  17. Apr 15, 20258-K
    Director or officer changeItem 5.02
  18. Mar 19, 20258-K
    Shareholder vote resultsItem 5.07
  19. Feb 7, 20258-K
    Director or officer changeItem 5.02
  20. Dec 18, 20248-K
    Director or officer changeItem 5.02
  21. Nov 26, 202410-K
    Annual report (10-K)10 risk factors added, 0 removed
  22. Nov 29, 202310-K
    Annual report (10-K)4 risk factors added, 0 removed

Peers

Companies in the same industry in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.

CompanyRevenueFree cash flowThrough
Axsome Therapeutics AXSM$0.8B−$0.1BJun 30, 2026
Repligen RGEN$0.8B$0.1BJun 30, 2026
Caris Life Sciences CAI$1.0B$0.1BJun 30, 2026
Insmed INSM$1.1B−$0.8BJun 30, 2026
Halozyme HALO$1.7B$0.8BJun 30, 2026
Moderna MRNA$2.2B−$1.2BJun 30, 2026
Exelixis EXEL$2.4B$1.2BJul 3, 2026
United Therapeutics UTHR$3.1B$1.1BJun 30, 2026

Identity

SEC CIK
879407
LEI
549300O3CSB8T7OZ3D66
Wikidata
Q113530745

Built from SEC EDGAR filings (public domain), the Guidance and KPI Ledgers, Palanor Discourse, U.S. Department of Labor filings, USPTO, USAspending and Senate lobbying records, and rights-checked news headlines. Updated nightly; this page was built Oct 22, 2026. How the Dossier is built

S&P 500, S&P 100, S&P MidCap 400 and Dow Jones Industrial Average are trademarks of S&P Dow Jones Indices LLC or its affiliates; Nasdaq-100 is a trademark of Nasdaq, Inc.; Russell 1000 is a trademark of FTSE Russell. Membership is shown for identification only. Palanor is not affiliated with or endorsed by the index owners.

Cookies

We only use essential cookies to keep you signed in and remember your theme. No analytics, no tracking, no ads. See the Privacy Policy for the full read.